Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476592 · ClinicalTrials.gov registry record · NA
A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors
A NA study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT01476592 is a NA study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 7 participants.
The verdict
NCT01476592, a NA study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
Resveratrol has been shown to activate a protein called Notch-1. Signaling of Notch-1 has been shown to prevent tumor cell growth. Resveratrol has also been shown to prevent growth of tumors in mice. The purpose of this study is to examine the effects of resveratrol and Notch-1 on neuroendocrine tumor tissue and to examine how people with neuroendocrine tumors who take resveratrol for up to three months tolerate the product.
Interventions
- DIETARY_SUPPLEMENT Resveratrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-12 |
| Est. Completion | 2018-10-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01476592
The ClinicalTrials.gov registry entry for NCT01476592 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Resveratrol is the first listed.
NCT01476592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01476592 about?
NCT01476592 is a clinical study titled "A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors". Resveratrol has been shown to activate a protein called Notch-1. Signaling of Notch-1 has been shown to prevent tumor cell growth. Resveratrol has also been shown to prevent growth of tumors in mice. The purpose of this study is to examine the effects of resveratrol and Notch-1 on neuroendocrine tum...
What is the current status of trial NCT01476592?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2011-12. Estimated completion is 2018-10-11.
What interventions are being tested in trial NCT01476592?
The interventions under investigation include: Resveratrol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01476592?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.